Distinct Temporal Phases in the Behavioral Pharmacology of LSD: Dopamine D2 Receptor-Mediated Effects in the Rat and Implications for Psychosis

Total Page:16

File Type:pdf, Size:1020Kb

Distinct Temporal Phases in the Behavioral Pharmacology of LSD: Dopamine D2 Receptor-Mediated Effects in the Rat and Implications for Psychosis Psychopharmacology (2005) 180: 427–435 DOI 10.1007/s00213-005-2183-9 ORIGINAL INVESTIGATION Danuta Marona-Lewicka . Ronald A. Thisted . David E. Nichols Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis Received: 13 July 2004 / Accepted: 6 January 2005 / Published online: 19 February 2005 # Springer-Verlag 2005 Abstract Rationale: The effect of LSD in humans has second temporal phase that involves dopaminergic path- been described as occurring in two temporal phases. The ways would be consistent with the widespread belief that behavioral effects in rats also occur in two temporal phases: excessive dopaminergic activity may be an underlying an initial suppression of exploration followed by increased cause of paranoid psychosis. locomotor activity. Objectives: We decided to investigate . this phenomenon from the perspective that the pharmacol- Keywords LSD Drug discrimination 5-HT2A . ogy might have relevance to the neurochemical mecha- Serotonin Dopamine D2 Schizophrenia Rat nisms underlying psychosis. Methods: Twenty-five male Sprague–Dawley rats were trained to discriminate LSD (186 nmol/kg, 0.08 mg/kg, i.p.) with a 30-min preinjection Introduction time (LSD-30, N=12) and LSD (372 nmol/kg, 0.16 mg/kg, i.p.) with a 90-min preinjection time (LSD-90, N=13) from LSD is the most potent known hallucinogenic substance, saline, using a two-lever, food-reinforced operant condi- with high affinity for a number of brain receptors (see tioning task. Results: LSD (186 or 372 nmol/kg, 0.08 or Nichols 2004 for a review). Although virtually all research 0.16 mg/kg) given 30 min prior to training produced a cue on hallucinogens, both clinical and preclinical, has focused that was completely antagonized by 5-HT2A antagonists on a unitary pharmacology for these substances, Freedman and lasted no longer than 1 h. LSD (372 nmol/kg, 0.16 mg/ (1984) has described the effects of LSD in humans as kg) injected 90 min before training produced a cue that was occurring in two temporal phases: a “psychedelic experi- not fully blocked by 5-HT2A antagonists, but instead was ence” in the early phase, with “meaningfulness and por- significantly inhibited by haloperidol. In these rats, sub- tentousness” as the prime characteristics, and a second stitution no longer occurred with the 5-HT2 agonists DOI phase that is “clearly a paranoid state.” This latter phase or LSD (30 min preinjection), but full substitution was develops about 4–6 h after LSD administration, and at obtained with the D2 agonists apomorphine, N-propyldi- times out to 10 h postdrug, subjects given LSD “...regularly hydrexidine, and quinelorane. Conclusion: The discrimi- report... they had been at the least self-centered, and usually native stimulus effect of LSD in rats occurs in two phases, suspicious, with ideas of reference or even paranoid con- and these studies provide evidence that the later temporal victions” (Freedman 1984). Freedman noted on several phase is mediated by D2 dopamine receptor stimulation. A occasions that this effect continued to be unnoticed and unstudied in research with hallucinogens. Further, he drew parallels between this later paranoid phase and amphet- amine psychosis in man and emphasized the possibility that D. Marona-Lewicka . D. E. Nichols (*) Department of Medicinal Chemistry and Molecular clues to understanding psychosis might be found in this Pharmacology, Purdue University, “paranoid” phase of LSD intoxication. Heine Pharmacy Building, 575 Stadium Mall Dr., We decided to investigate this phenomenon from the West Lafayette, IN, 47907-2091, USA perspective that the pharmacology might have relevance to e-mail: [email protected] Tel.: +1-765-4941461 the neurochemical mechanisms underlying psychosis. Fur- Fax: +1-765-4946790 thermore, we reasoned that Freedman’s observation might have relevance to the use of 5-HT2A antagonists in the R. A. Thisted treatment of some forms of psychosis because LSD and Department of Health Studies, Statistics, and Anesthesia/ Critical Care, The University of Chicago, other hallucinogens are thought to act principally as 5- 5841 S Maryland Avenue, HT2A agonists (Nichols 2004). It also seemed possible that Chicago, IL, 60637, USA the incidence of “bad trips” with LSD could be related to 428 the nature of the underlying pharmacology in the later LSD (2 h) prior to amphetamine potentiated the amphet- temporal phase of LSD intoxication. amine interoceptive cue in a drug discrimination paradigm In contrast to this observation about LSD, there is no in rats by shifting the amphetamine dose–response curve indication in the literature of a parallel in the psychophar- to the left (Marona-Lewicka and Nichols 1997). Those re- macology of hallucinogenic phenethylamines or simple sults suggested that the enhanced behavioral response to tryptamines. That is, reports of intoxication with these other amphetamine might be due either to an increased sensitivity agents appear to describe a unitary psychopharmacology of dopaminergic neurons or to an enhanced release of with typical dose–response curves (Shulgin and Shulgin dopamine by amphetamine (Marona-Lewicka and Nichols 1991, 1997). We therefore speculated that the two temporal 1997). intoxication “phases” of LSD were not related simply to 5- Nevertheless, the acute (15–30 min prior to testing) HT2 agonist activity. These observations led us to hypo- discriminative cue of LSD is clearly mediated by activation thesize that a “two-phase” temporal action was unique to of the 5-HT2A receptor (Colpaert et al. 1982; Colpaert and LSD and was related to some pharmacological property of Janssen 1983; Glennon et al. 1983, 1984; Glennon 1999; LSD that distinguished it from other chemical classes of Ismaiel et al. 1993; Leysen et al. 1982; Schreiber et al. 1994; hallucinogens. Winter 1994; Winter and Rabin 1988; Winter et al. 1999). A significant pharmacological difference between LSD Furthermore, time–response curves in rats given LSD and other types of hallucinogens is the direct dopaminergic 30 min prior to training showed a maximum of the 5-HT2A- effect of LSD, which is not a component of the pharma- mediated discriminative cue at about 30 min, with a loss cology of phenethylamine- and tryptamine-type hallucino- of the cue by about 1 h. We reasoned, therefore, that if gens. Dopaminergic effects of LSD have been recognized rats discriminated an LSD cue at longer pretreatment for many years (see Watts et al. 1995 and references there- times, it would likely be mediated by other pharmacolo- in), but the relevance of these actions to the psychophar- gical processes. In particular, if LSD sensitized the do- macology of LSD has never been fully appreciated. In view pamine system, as we had shown in our amphetamine of the recognized role of dopamine in psychosis (Seeman studies (Marona-Lewicka and Nichols 1997), rats might 1987; Bennett 1998; Carlsson 2001), we felt that a closer also be more sensitive to the dopaminergic effects of LSD focus in this area might be fruitful. Early drug discrimi- at later time periods. nation studies did note that LSD substituted partially (70– In the present study, a drug discrimination procedure in 80%) for the nonselective dopamine agonist apomorphine, rats was used to evaluate the discriminative stimulus effect and that apomorphine was able to generate 50% substitu- of LSD administered 90 min prior to testing, at a time when tion in LSD-trained rats (Holohean et al. 1982). These the 5-HT2A receptor-mediated cue was no longer signif- authors concluded that although serotonin plays a promi- icant. These rats were compared with rats trained using our nent role in the discriminative stimulus effects of LSD, standard protocol where LSD is administered 30 min prior dopamine receptor activation is a secondary factor in the to training. LSD cue. Holohean et al. (1982) further suggested that the dopaminergic effect of LSD might become evident in drug discrimination only when rats were trained to “attend” to Material and methods dopamine receptor activation. There has never been any evidence from drug discrimination experiments, however, Animals that the nature of the LSD discriminative cue might be time-dependent. Twenty-five male Sprague–Dawley rats (Harlan Labora- Evidence from animal studies of time-dependent behav- tories, Indianapolis, IN) weighing 180–200 g at the begin- ioral pharmacology for LSD comes from the studies of ning of the study were used as subjects. Rats were divided Mittman and Geyer (1991), who showed that LSD-induced into two groups and trained to discriminate LSD (186 nmol/ behavioral effects in rats occurred in two temporal phases: kg, 0.08 mg/kg, i.p.) with a 30-min preinjection time (LSD- an initial suppression of behavioral responding, followed by 30, N=12) and LSD (372 nmol/kg, 0.16 mg/kg, i.p.) with a a subsequent increase in locomotor activity that was not 90-min preinjection time (LSD-90, N=13) from saline, observed with other serotonergic agonists. Using pretreat- using a two-lever, food-reinforced operant conditioning ment with ritanserin and/or propanolol, these workers con- task. None of the rats had previously received drugs or cluded that the two temporal phases of LSD effects in rats behavioral training. Water was freely available in the in- were mediated by different serotonergic or β-adrenergic dividual home cages, and a rationed amount of supplemen- receptors. Due to the limited number of pretreatments that tal feed (LabDiet-5001, PMI, Nutrition International, LLC, were employed in that study, and the possibility of dopa- Brentwood, MO) was made available after experimental mine–serotonin functional interactions, it is not possible to sessions so as to maintain ∼80% of free-feeding weight. deduce clearly a mechanistic basis for the effects of LSD Lights were on from 0700 to 1900 h. The laboratory and observed in that study.
Recommended publications
  • D2 Receptors in the Paraventricular Nucleus Regulate Genital Responses and Copulation in Male Rats
    Pharmacology Biochemistry & Behavior, Vol. 39, pp. 177-181. ~ Pergamon Press plc, 1991. Printed in the U.S.A. 00914057/91 $3.00 + .00 D2 Receptors in the Paraventricular Nucleus Regulate Genital Responses and Copulation in Male Rats ROBERT C. EATON, VINCENT P, MARKOWSKI, LUCILLE A. LUMLEY, JAMES T. THOMPSON, JASON MOSES AND ELAINE M. HULL 1 Department of Psychology, State University of New York at Buffalo, Amherst, NY 14260 Received 30 April 1990 EATON, R. C., V. P. MARKOWSKI, L. A. LUMLEY, J. T. THOMPSON, J. MOSES AND E. M. HULL. D2 receptors in the paraventricular nucleus regulate genital responses and copulation in male rats. PHARMACOL BIOCHEM BEHAV 39(1) 177- 181, 1991.--The D2 dopamine receptor agonist quinelorane (LY-163502), microinjected into the paraventricular nucleus (PVN), affected genital responses of restrained supine male rats in a biphasic dose-dependent fashion. A moderate dose (1 Ixg) facilitated penile responses (intense erections and penile movements), and decreased the latency to the first response. A high dose of quinelorane (10 Ixg) facilitated seminal emission while inhibiting penile responses. The addition of the D1 antagonist SCH-23390 to the 1 ixg dose of quinelorane potentiated quinelorane's increase in seminal emission. We suggest that D1 receptors in the PVN may be antagonistic to D2 receptor-mediated seminal emission, and possibly also penile responses. In copulation tests 1 ~g quinelorane decreased mount latency, whereas 10 ixg quinelorane increased mount and intromission latencies and slowed copula- tory rate. Both 1 and 10 Ixg quinelorane, and also 1 and 10 Ixg of the mixed D1 and D2 agonist apomorphine, decreased the number of intromissions preceding ejaculation.
    [Show full text]
  • Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation
    www.sciencemag.org/cgi/content/full/327/5963/348/DC1 Supporting Online Material for Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation Jason Rihel,* David A. Prober, Anthony Arvanites, Kelvin Lam, Steven Zimmerman, Sumin Jang, Stephen J. Haggarty, David Kokel, Lee L. Rubin, Randall T. Peterson, Alexander F. Schier* *To whom correspondence should be addressed. E-mail: [email protected] (A.F.S.); [email protected] (J.R.) Published 15 January 2010, Science 327, 348 (2010) DOI: 10.1126/science.1183090 This PDF file includes: Materials and Methods SOM Text Figs. S1 to S18 Table S1 References Supporting Online Material Table of Contents Materials and Methods, pages 2-4 Supplemental Text 1-7, pages 5-10 Text 1. Psychotropic Drug Discovery, page 5 Text 2. Dose, pages 5-6 Text 3. Therapeutic Classes of Drugs Induce Correlated Behaviors, page 6 Text 4. Polypharmacology, pages 6-7 Text 5. Pharmacological Conservation, pages 7-9 Text 6. Non-overlapping Regulation of Rest/Wake States, page 9 Text 7. High Throughput Behavioral Screening in Practice, page 10 Supplemental Figure Legends, pages 11-14 Figure S1. Expanded hierarchical clustering analysis, pages 15-18 Figure S2. Hierarchical and k-means clustering yield similar cluster architectures, page 19 Figure S3. Expanded k-means clustergram, pages 20-23 Figure S4. Behavioral fingerprints are stable across a range of doses, page 24 Figure S5. Compounds that share biological targets have highly correlated behavioral fingerprints, page 25 Figure S6. Examples of compounds that share biological targets and/or structural similarity that give similar behavioral profiles, page 26 Figure S7.
    [Show full text]
  • Certificate of Analysis
    Print Date: Jan 15th 2016 Certificate of Analysis www.tocris.com Product Name: Quinelorane hydrochloride Catalog No.: 1519 Batch No.: 1 CAS Number: 97548-97-5 IUPAC Name: (5aR,9aR)-5,5a,6,7,8,9,9a,10-Octahydro-6-propylpyrido[2,3-g]quinazolin-2-amine dihydrochloride 1. PHYSICAL AND CHEMICAL PROPERTIES Batch Molecular Formula: C14H22N4.2HCl.2H2O Batch Molecular Weight: 355.3 Physical Appearance: Off-white crystalline solid Solubility: water to 25 mM Storage: Desiccate at RT Batch Molecular Structure: 2. ANALYTICAL DATA Melting Point: At 290°C HPLC: Shows >99.8% purity 1H NMR: Consistent with structure Mass Spectrum: Consistent with structure Microanalysis: Carbon Hydrogen Nitrogen Theoretical 47.33 7.94 15.77 Found 47.23 7.76 15.79 Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use bio-techne.com North America China Europe Middle East Africa Rest of World [email protected] Tel: (800) 343 7475 [email protected] Tel: +44 (0)1235 529449 www.tocris.com/distributors [email protected] Tel: +86 (21) 52380373 Tel:+1 612 379 2956 Print Date: Jan 15th 2016 Product Information www.tocris.com Product Name: Quinelorane hydrochloride Catalog No.: 1519 Batch No.: 1 CAS Number: 97548-97-5 IUPAC Name: (5aR,9aR)-5,5a,6,7,8,9,9a,10-Octahydro-6-propylpyrido[2,3-g]quinazolin-2-amine dihydrochloride Description: Storage: Desiccate at RT Dopamine D and D receptor agonist; K values are 5.7 and 3.4 23 i Solubility & Usage Info: nM respectively. water to 25 mM Physical and Chemical Properties: Stability and Solubility Advice: Batch Molecular Formula: C14 H 22 N 4 .2HCl.2H2 O Some solutions can be difficult to obtain and can be encouraged Batch Molecular Weight: 355.3 by rapid stirring, sonication or gentle warming (in a 45-60°C Physical Appearance: Off-white crystalline solid water bath).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0208029 A1 Barlow Et Al
    US 20070208029A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0208029 A1 Barlow et al. (43) Pub. Date: Sep. 6, 2007 (54) MODULATION OF NEUROGENESIS BY PDE Related U.S. Application Data INHIBITION (60) Provisional application No. 60/729,366, filed on Oct. (75) Inventors: Carrolee Barlow, Del Mar, CA (US); 21, 2005. Provisional application No. 60/784,605, Todd A. Carter, San Diego, CA (US); filed on Mar. 21, 2006. Provisional application No. Kym I. Lorrain, San Diego, CA (US); 60/807,594, filed on Jul. 17, 2006. Jammieson C. Pires, San Diego, CA (US); Kai Treuner, San Diego, CA Publication Classification (US) (51) Int. Cl. A6II 3 L/506 (2006.01) Correspondence Address: A6II 3 L/40 (2006.01) TOWNSEND AND TOWNSEND AND CREW, A6II 3/4I (2006.01) LLP (52) U.S. Cl. .............. 514/252.15: 514/252.16; 514/381: TWO EMBARCADERO CENTER 514/649; 514/423: 514/424 EIGHTH FLOOR (57) ABSTRACT SAN FRANCISCO, CA 94111-3834 (US) The instant disclosure describes methods for treating dis eases and conditions of the central and peripheral nervous (73) Assignee: BrainCells, Inc., San Diego, CA (US) system by stimulating or increasing neurogenesis. The dis closure includes compositions and methods based on use of (21) Appl. No.: 11/551,667 a PDE agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the forma (22) Filed: Oct. 20, 2006 tion of new nerve cells. Patent Application Publication Sep. 6, 2007 Sheet 1 of 6 US 2007/0208029 A1 Figure 1: Human Neurogenesis Assay: budilast + Captopril Neuronal Differentiation budilast + Captopril ' ' ' 'Captopril " " " 'budilast 10 Captopril Concentration 10-8.5 10-8.0 10-7.5 10-7.0 10-6.5 10-6.0 10-5.5 10-5.0 10-4.5 10-40 ammammam 10-9.0 10-8.5 10-8-0 10-75 10-7.0 10-6.5 10-6.0 10-5.5 10-50 10-4.5 Conc (M) Ibudilast Concentration Patent Application Publication Sep.
    [Show full text]
  • Sex Differences in Serotonergic and Dopaminergic Mediation of LSD Discrimination in Rats
    Western Michigan University ScholarWorks at WMU Dissertations Graduate College 8-2017 Sex Differences in Serotonergic and Dopaminergic Mediation of LSD Discrimination in Rats Keli A. Herr Western Michigan University, [email protected] Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Psychology Commons Recommended Citation Herr, Keli A., "Sex Differences in Serotonergic and Dopaminergic Mediation of LSD Discrimination in Rats" (2017). Dissertations. 3170. https://scholarworks.wmich.edu/dissertations/3170 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. SEX DIFFERENCES IN SEROTONERGIC AND DOPAMINERGIC MEDIATION OF LSD DISCRIMINATION IN RATS by Keli A Herr A dissertation submitted to the Graduate College in partial fulfillment of the requirements for the degree of Doctor of Philosophy Psychology Western Michigan University August 2017 Doctoral Committee: Lisa Baker, Ph.D., Chair Cynthia Pietras, Ph.D. Heather McGee, Ph.D. Missy Peet, Ph.D. SEX DIFFERENCES IN SEROTONERGIC AND DOPAMINERGIC MEDIATION OF LSD DISCRIMINATION IN RATS Keli A. Herr, Ph.D. Western Michigan University After decades of opposition, a resurgence of interest in the psychotherapeutic potential of LSD is gaining acceptance in the medical community. Future acceptance of LSD as a psychotherapeutic adjuvant may be predicated on knowledge about its neural mechanisms of action. Preclinical drug discrimination assay offers an invaluable model to determine the neural mechanisms underlying LSD’s interoceptive stimulus effects.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0220580 A1 Rubin Et Al
    US 2016O220580A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0220580 A1 Rubin et al. (43) Pub. Date: Aug. 4, 2016 (54) SMALL MOLECULESCREENING FOR (60) Provisional application No. 61/497,708, filed on Jun. MOUSE SATELLITE CELL PROLIFERATION 16, 2011. (71) Applicant: PRESIDENT AND FELLOWS OF Publication Classification HARVARD COLLEGE, Cambridge, (51) Int. Cl. MA (US) A 6LX3/553 (2006.01) (72) Inventors: Lee L. Rubin, Wellesley, MA (US); A613 L/496 (2006.01) Amanda Gee, Alexandria, VA (US); A613 L/4439 (2006.01) Amy J. Wagers, Cambridge, MA (US) A613 L/404 (2006.01) (52) U.S. Cl. CPC ............. A6 IK3I/553 (2013.01); A61 K3I/404 (21) Appl. No.: 15/012,656 (2013.01); A61 K3I/496 (2013.01); A61 K 31/4439 (2013.01) (22) Filed: Feb. 1, 2016 (57) ABSTRACT The invention provides methods for inducing, enhancing or Related U.S. Application Data increasing satellite cell proliferation, and an assay for screen (63) Continuation-in-part of application No. 14/126,716, ing for a candidate compound for inducing, enhancing or filed on Jun. 13, 2014, now Pat. No. 9.248,185, filed as increasing satellite cell proliferation. Also provided are meth application No. PCT/US2012/042964 on Jun. 18, ods for repairing or regenerating a damaged muscle tissue of 2012. a Subject. Patent Application Publication Aug. 4, 2016 Sheet 1 of 44 US 2016/0220580 A1 FIG. A Patent Application Publication Aug. 4, 2016 Sheet 2 of 44 US 2016/0220580 A1 FIG. C. FIG. 2A Patent Application Publication Aug.
    [Show full text]
  • Dopamine D4 Receptor, but Not the ADHD-Associated D4.7 Variant, Forms Functional Heteromers with the Dopamine D2S Receptor in Th
    Molecular Psychiatry (2012) 17, 650–662 & 2012 Macmillan Publishers Limited All rights reserved 1359-4184/12 www.nature.com/mp ORIGINAL ARTICLE Dopamine D4 receptor, but not the ADHD-associated D4.7 variant, forms functional heteromers with the dopamine D2S receptor in the brain S Gonza´lez1, C Rangel-Barajas2, M Peper3, R Lorenzo3, E Moreno1, F Ciruela4, J Borycz5, J Ortiz6, C Lluı´s1, R Franco7, PJ McCormick1, ND Volkow8, M Rubinstein3, B Floran2 and S Ferre´ 5 1Department of Biochemistry and Molecular Biology, Centro de Investigacio´n Biome´dica en Red sobre Enfermedades Neurodegenerativas, University of Barcelona, Barcelona, Spain; 2Departamento de Fisiologı´a, Biofı´sica y Neurociencias, Centro de Investigacio´n y de Estudios Avanzados del Instituto Polite´cnico Nacional, Me´xico D.F., Me´xico; 3Departamento de Fisiologı´a y Biologı´a Molecular y Celular, Instituto de Investigaciones en Ingenierı´a Gene´tica y Biologı´a Molecular, Consejo Nacional de Investigaciones Cientı´ficas y Te´cnicas, Buenos Aires, Argentina; 4Unitat de Farmacologia, Departament Patologia i Terape`utica Experimental, Universitat de Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain; 5CNS Receptor-Receptor Interactions Unit, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA; 6Department of Biochemistry and Molecular Biology, Neuroscience Institute, Universitat Auto´noma de Barcelona, Bellaterra, Spain; 7Departamento de Neurociencias, Centro de Investigacio´nMe´dica Aplicada, Universidad de Navarra, Pamplona, Spain and 8National Institute on Drug Abuse, National Institutes of Health, Bethesda MD, USA Polymorphic variants of the dopamine D4 receptor have been consistently associated with attention-deficit hyperactivity disorder (ADHD). However, the functional significance of the risk polymorphism (variable number of tandem repeats in exon 3) is still unclear.
    [Show full text]
  • D1, Not D2, Dopamine Receptor Activation Dramatically Improves MPTP
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.20.305375; this version posted September 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. TITLE PAGE For repository in: bioRXiv D1, not D2, dopamine receptor activation dramatically improves MPTP- induced parkinsonism unresponsive to levodopa Richard B. Mailman, Ph.D. [email protected] Yang Yang. Ph.D. [email protected] Xuemei Huang, M.D., Ph.D. [email protected] Departments of Pharmacology and Neurology Penn State University College of Medicine Hershey PA 17033 Corresponding Author: Professor Richard B. Mailman Penn State University College of Medicine 500 University Dr., R130 Hershey PA 17033-0850 Phone: (717)531-3666 Email: [email protected] ` bioRxiv preprint doi: https://doi.org/10.1101/2020.09.20.305375; this version posted September 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. ABSTRACT Levodopa is the Parkinson’s disease standard-of-care, but continued loss of dopamine neurons with disease progression decreases its bioconversion to dopamine, leading to increased side effects and decreased efficacy. In theory, dopamine agonists could equal levodopa, but no approved oral “dopamine agonist” matches the efficacy of levodopa. Although there are consistent data in both primate models and in Parkinson’s disease showing that selective high intrinsic activity D1 agonists can equal levodopa, there are no data on whether such compounds would be effective in severe disease when levodopa efficacy is lower or even absent.
    [Show full text]
  • Sfn2015 Items of Interest
    Presentations and Posters of Interest Society for Neuroscience Meeting (2015) 34.01/A100. Estradiol rapidly attenuates ORL-1 receptor-mediated inhibition of proopiomelanocortin neurons via Gq-coupled, membrane-initiated signaling *K. M. CONDE1, C. MEZA2, M. KELLY3, K. SINCHAK4, E. WAGNER2; 1Grad. Col. of Biomed. Sci., 2Col. of Osteo. Med. of the Pacific, Western Univ. of Hlth. Sci., Pomona, CA; 3 Dept. of Physiol. & Pharmacol., Oregon Hlth. and Sci. Univ., Portland, OR; 4California State University, Long Beach, Long Beach, CA Ovarian estrogens act through multiple receptor signaling mechanisms that converge on hypothalamic arcuate nucleus (ARH) proopiomelanocortin (POMC) neurons. A subpopulation of these neurons project to the medial preoptic nucleus (MPN) to regulate lordosis. Orphanin FQ/nociception (OFQ/N) via its opioid-like receptor (ORL-1) regulates lordosis through direct actions on these MPN-projecting POMC neurons. Based o an ever-burgeoning precedence for fast steroid actions, we explored whether estradiol excites ARH POMC neurons by rapidly attenuating inhibitory ORL-1 signaling in these cells. Experiments were carried out in hypothalamic slices prepared from ovariectomized female rats injected one-week prior with the retrograde tracer Fluorogold into the MPN. During electrophysiologic recordings, cells were held at or near -60 mV. Post-hoc identification of neuronal phenotype was determined via immunohistofluorescence. In vehicle-treated slices OFQ/N caused a robust outward current/hyperpolarization via activation of GIRK channels. This OFQ/N-induced outward current was attenuated by 17-β estradiol (E2, 100nM). The 17α enantiomer of E2 had n effect. The OFQ/N-induced response was also attenuated by an equimolar concentration of E2 conjugated to BSA.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Behavioral Pharmacology of Dopamine D2 and D3 Receptor Agonists and Antagonists in Rats
    Behavioral Pharmacology of Dopamine D2 and D3 Receptor Agonists and Antagonists in Rats. by Gregory T. Collins A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Pharmacology) in The University of Michigan 2008 Doctoral Committee: Professor James H. Woods, Chair Professor Margaret E. Gnegy Professor Shaomeng Wang Assistant Professor Roger K. Sunahara © Gregory T. Collins 2008 DEDICATION This thesis is dedicated to my parents, Thomas and Shirley Collins, without whom none of this would have been possible. Your continual support and encouragement throughout all of my endeavors has meant more than you will ever know. Thank you. ii ACKNOWLEDGMENTS First and foremost, I would like to thank my mentor, James Woods. You have been an exceptional mentor to me; I have learned more than I could have ever hoped. It has been a pleasure to work with someone who is so passionate and knowledgable, someone who has not only continued to challenge me, but has also provided an outstanding environment in which to study behavioral pharmacolgy. I truly feel lucky to have been able to learn from you. Of course, I also have to thank Gail Winger who has been a second mentor to me throughout the years. The support, encouragement, guidance, and patience that the two of you have provided has made for an exceptional experience. Thank you. I would also like to thank my committee, James Woods, Roger Sunahara, Peggy Gnegy and Shaomeng Wang. I am grateful to have been able to work with and learn from all of you over the years.
    [Show full text]
  • OTHER REVIEW(S) FOOD and DRUG ADMINISTRATION Center for Drug Evaluation and Research Office of Prescription Drug Promotion ****Pre-Decisional Agency Information****
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 211150Orig1s000 OTHER REVIEW(S) FOOD AND DRUG ADMINISTRATION Center for Drug Evaluation and Research Office of Prescription Drug Promotion ****Pre-decisional Agency Information**** Memorandum Date: July 12, 2019 To: Brendan Muoio, Regulatory Project Manager Division of Psychiatry Products (DPP) Kimberly Updegraff, Associate Director for Labeling, DPP From: Dhara Shah, Regulatory Review Officer Office of Prescription Drug Promotion (OPDP) CC: Aline Moukhtara, Team Leader, OPDP Subject: OPDP Labeling Comments for WAKIX® (pitolisant) tablets, for oral use NDA: 211150 O-1 & O-2 In response to DPP’s consult request dated January 14, 2019, OPDP has reviewed the proposed product labeling (PI) and carton and container labeling for the original NDA submission for Wakix. PI: OPDP’s comments on the proposed labeling are based on the draft PI received by electronic mail from DPP (Brendan Muoio) on July 5, 2019, and are provided below. Carton and Container Labeling: OPDP has reviewed the attached proposed carton and container labeling submitted by the Sponsor and received by electronic mail from DPP (Brendan Muoio) on July 8, 2019, and we do not have any comments. Thank you for your consult. If you have any questions, please contact Dhara Shah at (240) 402-2859 or [email protected]. 26 Page(s) of Draft Labeling have been Withheld in Full as B4 (CCI/TS) immediately following this page 1 Reference ID: 4461481 Signature Page 1 of 1 -------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.
    [Show full text]